Cellectis Reports Full Year 2025 Financial Results and Provides Business Update

Cellectis reported full-year 2025 financial results and provided a business update. The company's pivotal Phase 2 trial for lasme-cel in r/r B-ALL is ongoing, with a 100% ORR in the target population and all patients becoming transplant-eligible. Phase 1 trials for lasme-cel in r/r NHL and eti-cel are also ongoing. The company expects pivotal Phase 2 first interim analysis for lasme-cel in Q4 2026 and BLA submission in 2028. Cash, cash equivalents, and fixed-term deposits totaled $211 million, providing runway into H2 2027.